Ascenion has negotiated a licence agreement between Medical School Hannover (MHH) and its spin-off Cardior Pharmaceuticals providing the company with exclusive and comprehensive rights to its lead candidate against heart failure. The licence further consolidates Cardior’s strong IP position in the field and highlights the candidate’s recent progress. The oligonucleotide-based compound targets certain regulatory microRNAs which play a crucial role in pathological restructuring processes in the heart that occur in about 20% of patients following a heart attack. In-vivo studies have shown that the candidate, by inhibiting the target microRNAs, not only stops the fatal restructuring of the heart, but actually reverses it. This could represent a breakthrough for millions of patients.
Based on these results, the company is now accelerating the preparation of clinical trials. Last year, Cardior closed a EUR 15 million financing round, providing the resources for its ambitious development plans.
Further information:
Website Cardior Pharmaceuticals